Cubist (CBST) Nearing Deal To Be Acquired For $102 A Share: Report

Drug giant Merck & Co Inc. (MRK) is reportedly in talks to acquire antibiotics maker Cubist Pharmaceuticals Inc. (CBST) for about $102 a share, valuing the company that makes drugs to fight superbugs, in the range of $8 billion, according to CNBC. It was not clear if Merck would pay for Cubist shares with cash, […] View the full post at: Cubist (CBST) Nearing Deal To Be Acquired For $102 A Share: Report Related posts: CIT Group Cuts Deal with Key Bondholders to Avoid Bankruptcy A Drug Stock With Potential For Solid Gain Yahoo – Google Deal To Be Investigated